Home/Pipeline/TK-254Rx

TK-254Rx

Acute Minor Sport Injury

Phase 2Active

Key Facts

Indication
Acute Minor Sport Injury
Phase
Phase 2
Status
Active
Company

About Teikoku Pharma

Teikoku Pharma USA, founded in 1999, is a commercial-stage biopharmaceutical company with deep expertise in transdermal drug delivery systems. The company leverages its proprietary Hydrohesive® and Matrix patch technologies to develop non-opioid pain management solutions and treatments for CNS disorders, with a pipeline featuring late-stage assets like TPU-006 for post-surgical pain. With a marketed product generating revenue and a strategic focus on global partnerships and licensing, Teikoku is positioned to address significant unmet needs in pain management and neurology.

View full company profile